Nonalcoholic fatty liver disease (NAFLD) has evolved from a relatively unknown disease to the most common cause of chronic liver disease worldwide. Breast cancer comprises a group of diseases with specific histopathological, molecular and clinical characteristics, with different clinical findings and responses to treatment, and with multiple entities. About two-thirds of breast cancers are hormone receptor-positive (estrogen receptors expression, progesterone receptors expression or both) and are susceptible to treatment with hormonal therapies such as tamoxifen and aromatase inhibitors. The aim of this study was to examine the impact of hormone therapy for breast cancer on the development of components of metabolic syndrome, one of the main precursors of the development of NAFLD in patients with breast cancer. Using transient elastography, the study shows the influence of hormone therapy on the development of steatosis and liver fibrosis. The effects of therapy on the development of insulin resistance (HOMA-IR scoring system) and changes in body composition defined by the BIA scale were also studied. In this retrospective study, 115 patients of the oncology outpatient clinic of the Rijeka Clinical Hospital Center, with an average age of 64, were included, who were subjected to hormone therapy with a complete blockage of estrogen production. FibroScan® and BIA scales were used for measurements. Blood analysis was also performed on the patients. The conducted study confirms previous views and completes previous research on the development of NAFLD in patients receiving hormonal treatment for breast cancer. Tamoxifen therapy is significantly associated with the risk of developing NAFLD, although the prognostic significance of tamoxifen-induced NAFLD on outcome and survival has not been sufficiently investigated. In this study, we have shown that aromatase inhibitors also have a statistically significant association with the development of NAFLD.